BSE SENSEX
30,465
S&P CNX
9,429
Granules India
CMP: INR149
TP: INR200 (+34%)
Combination of strong growth and multiple re-rating
From being one of the largest Paracetamol API manufacturers for regulated markets,
Granules India (GRAN) has now ventured into CRAMS and US Rx business, where it can
leverage its competitive advantage of being a high-quality, low-cost producer. Despite
delivering ~40% PAT CAGR over last five years, we expect GRAN to deliver ~35% PAT
20 May 2017
Update
| Sector:
Healthcare
Buy
Stock Info
Bloomberg
Equity Shares (m)
52-Week Range (INR)
1, 6, 12 Rel. Per (%)
M.Cap. (INR b)
M.Cap. (USD b)
Avg Val, INRm
Free float (%)
GRAN IN
229
157/91
4/28/-6
33.8
0.5
197.0
46.5
CAGR till FY20E. This will be led by (1) capacity expansion in the base business, 2)
doubling of revenues (INR2.3b in FY20E from INR1.0b in FY17) and expansion in EBITDA
margin (>30% in FY20E from ~21% in FY17) in Omnichem CRAMS JV, and 3) new US
generic business sales of ~USD85m in FY20 v/s nil currently.
Base business – augmented capacity to fuel growth; focus on formulations
to boost margins
Financials Snapshot (INR b)
2017 2018E 2019E
Y/E Mar
14.4
17.4
23.9
Net Sales
3.0
3.7
5.2
EBITDA
1.7
2.1
2.9
PAT
7.3
8.1
11.4
EPS (INR)
32.7
12.3
39.9
Gr. (%)
43.5
60.4
69.1
BV/Sh (INR)
20.0
16.4
17.6
RoE (%)
17.0
14.7
16.8
RoCE (%)
20.5
18.3
13.1
P/E (x)
3.4
2.5
2.2
P/BV (x)
Shareholding pattern (%)
As On
Mar-17 Dec-17 Mar-16
Promoter
53.5
51.9
51.1
DII
1.6
1.2
1.2
FII
10
6
6.4
Others
35
40.9
41.3
FII Includes depository receipts
Stock Performance (1-year)
Granules India
Sensex - Rebased
160
140
120
100
80
GRAN is among the largest manufacturers of Paracetamol and Ibuprofen APIs
for the regulated markets. Along with this, it has been supplying Metformin,
Guaifenesin and Methacarbamol API/PFI/formulations. Until FY17, ~85% of its
business has come from these five base molecules. A higher focus on
formulations over past 4-5 years (revenue contribution up >10%) has helped
GRAN expand its EBITDA margin from 11% in FY13 to ~21% in FY17.
Currently, API is running at 100% capacity and PFI at 73% utilization. The
company had planned to increase its API capacity by ~40% and PFI capacity by
>20% by March 2017, which will also help fuel growth in formulations (as the
company is dependent on backward integration). This will help grow the base
business at mid-to-high teens till at least FY20 (~16% CAGR over FY17-20E v/s
~7% in FY17).
US business – plans niche foray into Rx business
GRAN is planning to file ~25-30 ANDAs in the US till FY19E. Of these, ~10
complex ANDAs will be filed from its US-based Virginia facility and the rest
from its India-based facility in Gagilapur. The company has already filed two
complex generic ANDAs from its Virginia facility in March/April-17 (market size
of USD660m), where it expects to be 3
rd
/4
th
player at the time of launch
(2HFY19). We expect own new filings for GRAN to contribute USD50-60m in
FY20E.
The company has also acquired the marketing rights from US Pharma for its
four ANDAs (scheduled to be launched from late FY18E to FY19E). The market
size for these products is >USD4b, and revenue potential could be USD30-35m
in FY19E.
Although we are already building in R&D spend of ~USD12m for FY19E, full-
year revenue from own filings will start only FY20 onward. Despite this, we
estimate an improvement in the consolidated EBITDA margin by 100bp due to
traction in the base business and a shift in product mix toward formulations.
Kumar Saurabh
(Kumar.Saurabh@MotilalOswal.com); +91 22 6129 1519
Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.
Investors are advised to refer through important disclosures made at the last page of the Research Report.